The Manufacturers Life Insurance Company lifted its stake in shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) by 1.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,488 shares of the biopharmaceutical company’s stock after purchasing an additional 698 shares during the period. The Manufacturers Life Insurance Company owned 0.06% of Alder BioPharmaceuticals worth $430,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Legal & General Group Plc boosted its holdings in shares of Alder BioPharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 400 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Alder BioPharmaceuticals by 109.4% during the 2nd quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 8,140 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Alder BioPharmaceuticals by 8.4% during the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 1,734 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Alder BioPharmaceuticals during the 1st quarter worth approximately $564,000. Finally, Cornerstone Capital Management Holdings LLC. raised its position in shares of Alder BioPharmaceuticals by 13.4% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $349,000 after buying an additional 3,616 shares during the period. Institutional investors and hedge funds own 96.86% of the company’s stock.

Several analysts have recently commented on ALDR shares. Mizuho started coverage on shares of Alder BioPharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $32.00 price target on the stock. Royal Bank Of Canada started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $17.00 price target on the stock. Canaccord Genuity started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, October 26th. They set a “buy” rating and a $20.00 price target on the stock. BidaskClub raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Credit Suisse Group set a $11.00 price target on shares of Alder BioPharmaceuticals and gave the company a “hold” rating in a research report on Thursday, August 24th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. Alder BioPharmaceuticals has an average rating of “Buy” and a consensus target price of $28.07.

Shares of Alder BioPharmaceuticals, Inc. (ALDR) opened at $10.30 on Tuesday. Alder BioPharmaceuticals, Inc. has a 12-month low of $8.60 and a 12-month high of $26.70.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.29. During the same period in the previous year, the business posted ($0.70) earnings per share. research analysts forecast that Alder BioPharmaceuticals, Inc. will post -5.36 earnings per share for the current year.

In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,520 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $12.33, for a total value of $203,691.60. Following the sale, the insider now owns 116,452 shares of the company’s stock, valued at $1,435,853.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.60% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “The Manufacturers Life Insurance Company Buys 698 Shares of Alder BioPharmaceuticals, Inc. (ALDR)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/28/the-manufacturers-life-insurance-company-buys-698-shares-of-alder-biopharmaceuticals-inc-aldr.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.